Esperion Therapeutics, Inc. (ESPR)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EST
After hours:
| Previous close | 8.68 |
| Open | 8.47 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1100 |
| Day's range | 8.10 - 9.05 |
| 52-week range | 6.97 - 39.49 |
| Volume | |
| Avg. volume | 1,260,221 |
| Market cap | 253.846M |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -11.69 |
| Earnings date | 21 Feb 2022 - 25 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.91 |
- Zacks
Implied Volatility Surging for Esperion Therapeutics (ESPR) Stock Options
Investors need to pay close attention to Esperion Therapeutics (ESPR) stock based on the movements in the options market lately.
- GlobeNewswire
Esperion Presents Important New Science Highlighting Potential Benefits of NEXLETOL® (bempedoic acid) Tablets at American Heart Association Scientific Sessions 2021
- Analysis of pooled Phase 3 data showed that NEXLETOL [bempedoic acid (BA)] alone lowered LDL-C levels comparable to that of a moderate- or high-intensity statin (≥ 30%) in nearly 1 out of 3 of patients - - In patients with metabolic syndrome NEXLETOL lowered hemoglobin A1c (HbA1c), fasting plasma glucose and low-density lipoprotein cholesterol (LDL-C), at week 12 - - In healthy patients treatment with BA reduced fasting LDL-C, non- high-density lipoprotein cholesterol (HDL-C), and baseline hig
- Simply Wall St.
Esperion Therapeutics, Inc. (NASDAQ:ESPR): Are Analysts Optimistic?
Esperion Therapeutics, Inc. ( NASDAQ:ESPR ) is possibly approaching a major achievement in its business, so we would...
© 2021 Yahoo. All rights reserved.
